Thursday | 8 January, 2009
Stories about: MTR
- +
Financial results in brief 02/09/2005 10:03:11
Cancer therapy developer Meditech (ASX:MTR) has received an AusIndustry Commercial Ready Grant worth $2.988 million over the next three years towards the development and commercialisation of HyCAMP, its lead anti-cancer product which is in phase II clinical testing. Meditech has also reported a half year loss of $1.68 million and a cash balance of $3.4 million. - +
In brief: Meditech, Psivida, Regenera, Mesoblast 24/08/2005 14:59:34
Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing. - +
Meditech IDs new breast cancer target 19/07/2005 14:32:29
Victorian cancer biopharma Meditech Research (ASX:MTR) claims to have identified a hot new target for breast cancer therapy -- an enzyme called hyaluronic synthase 2 (HAS2), found in vesicles in cell membranes. - +
Meditech signs collaboration agreement with US firm Hyalose 08/07/2005 11:00:10
Cancer therapy developer Meditech (ASX:MTR) has signed a research and development collaboration agreement with Hyalose, a privately-owned US biotech company. - +
In brief: Psiron, pSivida, Meditech Research, Optiscan Imaging 16/06/2005 13:53:48
Greg Williams is Psiron's (ASC:PSX) new chief financial officer, a position he commenced on June 14. - +
'Heavy-hearted' Smith steps down from Amrad 20/05/2005 12:01:13
Pete Smith has resigned as CEO of Amrad (ASX:AML), along with chairman Bob Moses as chairman, following a board meeting yesterday. - +
In brief: Acrux, Meditech, Psivida 03/05/2005 15:04:24
Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan . - +
In brief: Starpharma, Proteome Systems, Meditech, C3, Biodiem 31/03/2005 15:58:26
Starpharma (ASX: SPL, USOTC:SPHRY) has appointed former Cerylid Biosciences chief executive officer Dr Jackie Fairley to the newly created position of chief operating officer. Fairley will begin her role with Starpharma toward the middle of 2005. - +
Financial results: Meditech and Optiscan 11/02/2005 14:45:54
Meditech Research (ASX: MTR) has reported that its revenues increased 90 per cent to AUD$679,495 while its net loss decreased marginally to $2.7 million during its financial year ending December 31, 2004. - +
In brief: ResMed, Meditech, Ventracor 04/02/2005 15:18:53
ResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31 Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million. - +
In brief: Chemeq; C3; Gropep; Starpharma; Meditech 16/12/2004 15:27:21
Non-executive director Paul Grujic and chief financial officer Ian Purdy today resigned from West Australian biotech Chemeq (ASX: CMQ).
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
Fujitsu Introduces First Netbook Series – Fujitsu M1010, the Comprehensive Solution for Work and Play. 2008-12-15 16:30:00+11
Kingston Technology Boosts DataTraveler 150 Capacity to 64GB 2008-12-09 15:30:00+11
IDC Says Asia/Pacific Excluding Japan IT Market Will Remain The Bright Spot... 2008-12-04 15:04:00+11
AOC Launches 18.5” Widescreen Green 16:9 LCD Monitor in Australia and New Zealand 2008-12-03 15:30:00+11
NComputing Appoints Country Manager for Australia, New Zealand, and South Pacific Islands 2008-12-03 00:43:00+11
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector.
